Published ahead of print on September 5, 2008, doi:10.1164/rccm.200803-391OC Am. J. Respir. Crit. Care Med., Volume 178, Number 10, November 2008, 1033-1039 A more recent version of this article appeared on November 15, 2008
Submitted on March 9, 2008 MUC5B is the Major Mucin in the Gel-phase of Sputum in Chronic Obstructive Pulmonary DiseaseSara Kirkham1,1 Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom; North West Lung Centre, University of South Manchester Hospital NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom, 2 North West Lung Centre, University of South Manchester Hospital NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom, 3 Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom, 4 North West Lung Centre, University of South Manchester Hospital NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom; Department of Cardiology and Respiratory Medicine, Hvidovre Hospital, Hvidovre, Denmark * To whom correspondence should be addressed. E-mail: jorgen.vestbo{at}manchester.ac.uk.
Rationale: Overproduction of mucus is a contributory factor in the progression of COPD. The polymeric mucins are major macromolecules in the secretion. Therefore, we hypothesized that the polymeric mucin composition or properties may be different in the sputum from individuals with COPD and smokers without airflow obstruction. Objectives: To determine the major polymeric mucins in COPD sputum and whether these are different in the sputum from individuals with COPD compared to smokers without airflow obstruction. Methods: The polymeric mucin composition of sputum from patients with COPD and smokers without airflow obstruction was analysed by western blotting analysis. The tissue localisation of the mucins was determined by immunohistochemistry, and their size distribution was analysed by rate-zonal centrifugation. Results: MUC5AC and MUC5B were the major mucins. MUC5AC was the predominant mucin in the smoker group whereas MUC5B was more abundant from the COPD patients with a significant difference in the ratio of MUC5B:MUC5AC (p=0.004); this ratio was correlated with FEV1 in the COPD group (r=0.63, p=0.01). The lower charged glycosylated form of MUC5B was more predominant in COPD (p = 0.012). No significant associations were observed with respect to gender, age and pack-year history. In both groups, MUC5AC was produced by surface epithelial cells and MUC5B by submucosal gland cells. Finally, there was a shift towards smaller mucins in the COPD group. Conclusions. Our data indicate that there are differences in mucin amounts and properties between smokers with and without COPD. Further studies are needed to examine how this may impact on disease progression. Key words: COPD, Mucus, Mucin, pathophysiology
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||